Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster session 20

1412P - SAKK 17/18-ORIGIN trial: Efficacy and safety from a multicenter phase II trial of gemcitabine and atezolizumab in patients with advanced NSCLC progressing on immune checkpoint inhibitors

Date

21 Oct 2023

Session

Poster session 20

Topics

Tumour Immunology;  Immunotherapy

Tumour Site

Non-Small Cell Lung Cancer

Presenters

Alessandra Curioni-Fontecedro

Citation

Annals of Oncology (2023) 34 (suppl_2): S755-S851. 10.1016/S0923-7534(23)01943-9

Authors

A. Curioni-Fontecedro1, L. Holer2, M. Frueh3, S. Weindler4, D. König5, A. Addeo6, C. Britschgi7, A. Rigutto8, C. Waibel9, A. Bettini10, F.W.F. Cerciello11, S. Hiltbrunner12, D.L. nguyen13, C. Zellweger14, J. Musilova15, R.A.F. von Moos16, M. Joerger17

Author affiliations

  • 1 Department Of Oncology, University Hospital Zurich, Switzerland, now at Cantonal Hospital Fribourg, 1700 - Fribourg/CH
  • 2 -, SAKK - Swiss Group for Clinical Cancer Research, 3008 - Bern/CH
  • 3 Departement Of Oncology, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 4 Medical Oncology Department, Kantonsspital St. Gallen, 9007 - St. Gallen/CH
  • 5 Medical Oncology Department, University Hospital Basel, 4031 - Basel/CH
  • 6 Oncology Dept., HUG - Hopitaux Universitaires de Geneve, 1205 - Geneva/CH
  • 7 Department Of Medical Oncology And Hematology, USZ - University Hospital Zürich, 8091 - Zurich/CH
  • 8 Faculty Of Science And Medicine, Department Of Medical-surgical Specialties, University of Zurich, Switzerland now at University of Fribourg, 1712 - Fribourg/CH
  • 9 Medical Oncology, Kantonsspital Baden, 5404 - Baden/CH
  • 10 Médical Oncology, HFR - Hopital Cantonal, 1700 - Fribourg/CH
  • 11 Medical Oncology Dept., Inselspital - Universitatsklinik fur Medizinische Onkologie, 3010 - Bern/CH
  • 12 Faculty Of Science And Medicine, University Hospital Zurich, Switzerland now at University of Fribourg, 1700 - Fribourg/CH
  • 13 Deaprtment Of Radiology And Nuclear Medicine, Stadtspital Zürich Triemli, 8063 - Zurich/CH
  • 14 Deaprtment Of Radiology, USZ - University Hospital Zurich - Institut für Diagnostische und Interventionelle Radiologie, 8091 - Zurich/CH
  • 15 Dept Of Statistics, SAKK - Swiss Group for Clinical Cancer Research, 3008 - Bern/CH
  • 16 Oncology/hematology Dept., KSGR - Kantonsspital Graubünden, 7000 - Chur/CH
  • 17 Medical Oncology And Hematology Department, Kantonsspital St. Gallen, 9007 - St. Gallen/CH

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Abstract 1412P

Background

A significant number of patients (pts) with advanced non-small cell lung cancer (NSCLC) do not respond to therapy with immune checkpoint inhibitors (ICI). After relapse, treatment options are limited. We have previously demonstrated in a preclinical in vivo model that the combination of ICI and gemcitabine (GEM) can overcome resistance to ICI or GEM alone. ORIGIN (NCT04480372) is a multicenter phase II trial of GEM and atezolizumab (ATEZO) in patients with advanced non-small cell lung cancer (NSCLC) and mesothelioma (MPM) progressing on ICI. Here we report the data of the NSCLC cohort.

Methods

Eligible pts had ECOG PS 0-2, with confirmed NSCLC stage IIIB-IV with disease recurrence or progression during or after ≥ prior line of ICI or chemo-ICI and available tissue for translational research. Pts received GEM (1000mg /m2 IV d1, 8 q3w) and ATEZO (1200 mg IV q3w). The primary endpoint (EP) was overall response rate (ORR) of the full analysis set (FAS) evaluated by independent radiological assessment. 35 pts were needed based on a one-sided type I error of 10% and a power of 80% for H1 ORR ≥25% compared to H0 ORR ≤11%. Key secondary EPs were progression free survival (PFS), disease control rat (DCR) at 18 weeks, duration of response (DoR), overall survival (OS) and safety.

Results

Between 03/2021 and 10/2021 37 pts were accrued and received GEM+ATEZO after a median of 2 prior lines of treatment (range 1-8). 36 patients were included in the FAS. Pts with ECOG PS 0, 1 and 2 were 25%, 56% and 19% resp; females represented 44% of pts and median age was 67y (48-80). At data cutoff, median follow-up was 17.6 mo. ORR was 31% (one-sided 90%CI: 20%, 95%CI: 16%-48%) and 22% of pts had stable disease. Median PFS was 4.0 mo (95% CI: 2.5-5.3), DCR at 18 weeks was 42% (95%CI: 26%-59%); median DoR was 5.2 mo (95% CI: 1.1-not reached) and median OS 8.2 mo (95% CI: 6.1-10.1). Treatment-related AEs occurred in 89% (G3-4, 59%) and led to discontinuation in 19% of pts. Extensive translational research on longitudinal blood samples is ongoing.

Conclusions

ORIGIN met its primary endpoint with an ORR of 31% in heavily pre-treated NSCLC patients with no unexpected toxicity profile of GEM or ATEZO.

Clinical trial identification

NCT04480372.

Editorial acknowledgement

Legal entity responsible for the study

SAKK (Swiss Group for Clinical Cancer Research).

Funding

Roche supported SAKK.

Disclosure

A. Curioni-Fontecedro: Financial Interests, Personal, Advisory Board: AstraZeneca, Bristol Meyer Squibb, Boehringer Ingelheim, MSD, Novartis, Amgen, Roche, Takeda, Janssen; Non-Financial Interests, Leadership Role: Swiss Academy for Clinical Cancer Research (SAKK); Non-Financial Interests, Principal Investigator, of clinical trials: Roche; Non-Financial Interests, Principal Investigator, Clinical Trials: Takeda, MSD, Bristol Meyer Squibb, Amgen. M. Frueh: Financial Interests, Personal, Research Grant: MSD, AstraZeneca; Financial Interests, Personal, Advisory Board: MSD, Roche, BMS, Pfizer, Takeda. S. Weindler: Financial Interests, Institutional, Advisory Board: Amgen; Financial Interests, Institutional, Research Funding: Merck, BMS; Financial Interests, Institutional, Other, Travel: Vifor, Eli Lilly. D. König: Financial Interests, Personal, Other, Consultant: AstraZeneca; Financial Interests, Personal, Speaker’s Bureau: Amgen, Sanofi; Financial Interests, Personal, Other, Travel: Amgen, Roche, Sanofi; Financial Interests, Personal, Advisory Board: AstraZeneca, Merck, MSD. A. Addeo: Financial Interests, Institutional, Advisory Board: BMS, AZD, Roche, Eli Lilly; Financial Interests, Personal, Advisory Board: Pfizer, Takeda, MSD; Financial Interests, Institutional, Invited Speaker: Novartis. C. Britschgi: Financial Interests, Personal, Advisory Board: AstraZeneca, Pfizer, Roche, Takeda, Janssen-Cilag, Boehringer Ingelheim, Merck, Sanofi; Financial Interests, Personal, Other, Travel: AstraZeneca, Amgen, Takeda. A. Bettini: Financial Interests, Personal, Advisory Board: MSD, Merk, Janssen; Other, Travel fees: Roche, Amgen; Other, Inscription fees: AstraZeneca. M. Joerger: Financial Interests, Institutional, Coordinating PI, Clinical study activity: Basilea, Bayer, BMS, Immunophotonics, MSD, Novartis, Roche; Financial Interests, Institutional, Other, Clinical study activity: DaiichySankyo; Financial Interests, Institutional, Local PI, Clinical study activity: Innomedica; Non-Financial Interests, Advisory Role: Novartis, AstraZeneca, Basilea, Bayer, BMS, Debiopharm, MSD, Roche, Sanofi. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.